Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
4,582
datasets available to search
ShareScore release 0.9.0
Dataset results
4,582 results for “chronic diseases”
Figure 1 in Detection of respiratory viruses and expression of inflammatory cytokines in patients with acute exacerbation chronic obstructive pulmonary disease in Mongolia China
Figure 1. Distribution of Viruses.
CancerEpiSys – Integrative analysis of epigenetic networks that determine the chronic lymphocytic leukemia disease state
<p>A public repository of data processed for Mallm, Iskar, Ishaque et. al. 2018 Linking aberrant chromatin features in chronic lymphocytic leukemia to deregulated transcription factor networks</p> <p><strong>Website:</strong> http://www.cancerepisys.org/cancerepisys/index.html</p> <p><strong>Github:</strong> https://github.com/CancerEpiSys/Mallm-et-al-processing-scripts</p> <p><strong>Research mission</strong></p> <p><em>CancerEpiSys</em> is a BMBF funded research project with the <a href="http://www.bmbf.de/foerderungen/15063.php">CancerSys program</a> that dissects the epigenetic networks associated with chronic lymphocytic leukemia (CLL) to develop novel diagnostic and therapeutic approaches for the disease. It has been initiated based on the emerging view that signals encoded in the DNA sequence, epigenetic modifications (e.g. DNA methylation, post-translational histone modifications), non-coding RNAs and nucleosome positioning are not independently regulated properties. Rather, these chromatin features are governed by an interconnected network of molecular processes that determine the cellular gene expression program. Any errors that occur in the interplay of these factors can lead to aberrant gene regulation associated with cancer. To rationalize the mode of action of novel ‘epigenetic’ drugs in cancer therapy that change properties of this network, we will dissect experimentally and mathematically the interdependence of these processes, focusing on CLL.</p> <p>The main objectives of <em>CancerEpiSys</em> are: (i) deciphering the relation of DNA sequence, epigenetic modifications, nucleosome positioning and aberrant gene expression in CLL, (ii) the identification of epigenetic network morphologies that describe the response to the epigenetic drugs panobinostat and 3-deazaneplanocin (DZNep) that inhibit histone deacetylases and methyltransferases, (iii) the characterization of epigenetic markers and chromatin features of CLL patient subgroups, and (iv) the integration of results into an analysis scheme for the epigenetic aberrations most relevant for prognostication, prediction of treatment relapse and stratification of patients with respect to therapeutic options. Moreover, our results will inform novel therapeutic approaches that target gene-expression programs at the epigenetic level to sensitize cancer cells towards apoptosis and anti-growth signals.</p>
The effectiveness of harvest for limiting wildlife disease: insights from 20 years of chronic wasting disease in Wyoming
<p>Data and code accompanying Moss et al. "The effectiveness of harvest for limiting wildlife disease: insights from 20 years of chronic wasting disease in Wyoming" (Ecological Applications). </p>
Data from: Discharge communication for chronic disease patients in three hospitals in India
OBJECTIVES <p>Poor discharge communication is associated with negative health outcomes in high-income countries. However, quality of discharge communication has received little attention in India and many other low and middle-income countries. Primary Objective To investigate verbal and documented discharge communication for chronic non-communicable disease (NCD) patients. Secondary objective To explore the relationship between quality of discharge communication and health outcomes.</p> METHODS: <p>Design Prospective study.</p> <p><strong>Setting:</strong> Three public hospitals in Himachal Pradesh and Kerala states, India.</p> <p><strong>Participants:</strong> 546 chronic NCD (chronic respiratory disease, cardiovascular disease or diabetes) patients. Piloted questionnaires were completed at admission, discharge and Five and eighteen-week follow-up covering health status, health-seeking behaviour and healthcare information exchange practices. Logistic regression was used to explore the relationship between quality of discharge communication and health outcomes.</p> <p><strong>Outcome Measures:</strong></p> <p><strong>Primary:</strong> Patient recall and experiences of verbal and documented discharge communication.</p> <p><strong>Secondary:</strong> Death, hospital readmission and self-reported deterioration of NCD/s.</p> RESULTS <p>All patients received discharge notes, which were predominantly on minimally structured sheets of paper (71%); 31% of notes contained all of the following information required for facilitating continuity of care: diagnosis, medication information, lifestyle advice, and follow-up instructions. Patient reports indicated notable variations in verbal information provided during discharge consultations; 50% received ongoing treatment/management information and 23% received lifestyle advice. Within 18 weeks of follow-up, 25 (5%) patients had died, 69 (13%) had been readmitted and 62 (11%) reported that their chronic NCD/s had deteriorated. Significant associations were found between low-quality documented discharge communication and death (AOR=3.00; 95% CI 1.27,7.06) and low-quality verbal discharge communication and self-reported deterioration of chronic NCD/s (AOR=0.46; 95% CI 0.25,0.83) within 18-weeks of follow-up.</p> CONCLUSIONS <p>Sub-optimal discharge practices may be compromising the continuity and safety of chronic NCD patient care. Structured protocols, documents and training are required to improve discharge communication, healthcare integration and overall NCD management.</p>
KidDO project update - quantitative proteomic and metabolomic analysis of five mouse models with chronic kidney disease
<p>Chronic kidney disease (CKD) is one of the most deadly diseases faced by patients and is a major global health and socioeconomic burden.CKD increases cardiovascular morbidity and premature mortality and decreases quality of life. Hypertension (HTN) and type 2 diabetes mellitus (T2DM), which are reaching epidemic levels, are major risk factors for CKD. CKD diagnosis and progression is based on estimated GFR (eGFR) and urinary albumin excretion. However, eGFR only has a predictive value in advanced disease and there is risk of progressive CKD in non-albuminuric individuals. Thus, there is an urgent need for new approaches for early detection of the most “at risk” individuals and identification of CKD signatures to aid in designing novel drugs and preventive measures that could ameliorate progression of CKD.</p> <p>Our overarching goal is to identify metabolites that predict kidney cell phenotypes during CKD and how crosstalk of these metabolites with the proteome drive CKD progression. We will integrate metabolomics and proteomic information from animal models of CKD with human CKD patient biopsies to identify common signatures in the tubulointerstitium that correlate with human pathophysiology.</p> <p>Here we provide quantitative proteomic and metabolomic datasets, as well as plasma and urine electrolyte measurements on five CKD mouse models.</p>
Adapting Clinical Practice Guidelines for Chronic Kidney Disease: Blood Pressure Management and Kidney Replacement Therapy in Adults and Children in the Saudi Arabian context using the GRADE-ADOLOPMENT methodology
<p>This compressed ZIP file includes three components</p> <p>The Full Guideline Document (FINAL COPY) for the <strong>2022 Saudi Guideline for Chronic Kidney Disease: Blood Pressure Management and Kidney Replacement Therapy in Adults and Children</strong></p> <p>In addition to two guideline reporting checklists to ensure the quality of this adoloped guideline:-</p> <p><strong>1- AGREE Reporting Checklist</strong></p> <p><strong>2- RIGHT-Ad@pt Checklist</strong></p> <p>As a supplementary to the submitted article entitled:_</p> <p><strong>Adapting Clinical Practice Guidelines for Chronic Kidney Disease: Blood Pressure Management and Kidney Replacement Therapy in Adults and Children in the Saudi Arabian context using the GRADE-ADOLOPMENT methodology</strong></p>
Intrinsic TGF-b Signaling Attenuates Proximal Tubule Mitochondrial Injury and Inflammation in Chronic Kidney Disease
<p>Bulk RNA sequencing processed count files for the article titled "Intrinsic TGF-b Signaling Attenuates Proximal Tubule Mitochondrial Injury and Inflammation in Chronic Kidney Disease", by Nlandu Khodo et al., in review. </p> <p>Corresponding GEO submission can be found here: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225545 </p>
Topological characterization of the retinal microvascular network visualized by portable fundus camera- effects of chronic disease (TREND2) database
<p><strong>Introduction</strong></p> <p><strong>T</strong>opological characterization of the <strong>R</strong>etinal microvascular n<strong>E</strong>twork visualized by portable fu<strong>ND</strong>us camera (<strong>TREND 2</strong>) is a database of digital color eye fundus images created as an addition to TREND database (https://zenodo.org/badge/DOI/10.5281/zenodo.4521044.svg).</p> <p>TREND 2 databse was created by medical professionals of the Faculty of Medicine of the University of Montenegro in 2023.</p> <p> </p> <p><strong>Purpose</strong></p> <p>1) to provide a standard that defines normal and abnormal retinal anatomy and microvascular geometry as it appears when visualized by the portable fundus camera</p> <p>2) to help the development of new methods for stratification of the risk for the development of various eye diseases, as well as systemic diseases that affect microvasculature</p> <p>3) to aid the development of biomarkers of accelerated aging</p> <p>4) to provide a standard that can be used to develop software for segmentation of retinal microvasculature, grading the quality of retinal digital images, and computer-aided diagnosis of systemic and chronic diseases.</p> <p>All color digital images were acquired with a hand-held portable, non-mydriatic MiiS HORUS Scope DEC 200 with 45º FOV and 2560 X 1920 pixel resolution.</p> <p> </p> <p><strong>Data</strong></p> <p>The TREND public database contains 28 color fundus images of old subjects (20 images from subjects with one or more chronic diseases such as type 2 diabetes mellitus, hypertension or Alzheimer's dementia- O_CD group, and 8 images from subjects with no chronic diseases- O_NCD group). Each image is associated with a corresponding binarized image of the manually segmented microvascular network.</p> <table> <caption>Inclusion and Exclusion Criteria</caption> <thead> <tr> <th scope="col">O_NCD group</th> <th scope="col">O_CD group</th> </tr> </thead> <tbody> <tr> <td><strong>Inclusion Criteria</strong></td> <td><strong>Inclusion Criteria</strong></td> </tr> <tr> <td>- at least 56 years old</td> <td>- at least 56 years old</td> </tr> <tr> <td> <p>- no current acute disease</p> <p>- no history of alcohol, or drug abuse, or psychiatric disease</p> </td> <td> <p>- no current acute disease</p> <p>- no history of alcohol, or drug abuse, or psychiatric disease</p> </td> </tr> <tr> <td> <p>- no history of alcohol, or drug abuse, or psychiatric disease</p> </td> <td>- no history of alcohol, or drug abuse, or psychiatric disease</td> </tr> <tr> <td>- negative history of any chronic disease</td> <td> <p>- controlled hypertension (blood pressure<140/90 mmHg), and/or</p> <p>- controlled type 2 diabetes mellitus, and/or</p> <p>- Alzheimer's dementia</p> </td> </tr> <tr> <td><strong>Exclusion Criteria</strong></td> <td><strong>Exclusion Criteria</strong></td> </tr> <tr> <td> <p>- presence of opacities of the transparent media in both eyes affecting</p> <p>- myopia ≥5 diopters</p> </td> <td> <p>- presence of opacities of the transparent media in both eyes affecting</p> <p>- myopia ≥5 diopters</p> </td> </tr> </tbody> </table> <p><strong>Files:</strong></p> <p>1_OLD WITH CHRONIC DISEASE_RAW (20 images in tif format)</p> <p>2_OLD WITH CHRONIC DISEASE_SEGMENTED (20 images in png format)</p> <p>3_OLD WITH NO CHRONIC DISEASE_RAW (8 images in tif format)</p> <p>4_OLD WITH NO CHRONIC DISEASE SEGMENTED (8 images in png format)</p> <p>5_ASSOCIATED DATA (xslx format)</p> <p>6_RETINAL PATHOLOGY (docx format)</p> <p> </p> <p> </p>
The gut microbiota in chronic obstructive pulmonary disease varies by CT-verified emphysema status
<p><strong><span>Background and aim</span> </strong></p> <p><span>The association of the gut microbiota to </span><span>chronic obstructive pulmonary disease (COPD)</span><span> phenotypes is underexplored. We aimed to compare</span><span> stool samples from COPD patients and healthy controls and relate findings to common COPD phenotypes. </span></p> <p><strong><span>Methods</span></strong></p> <p><span>Single-centre case-control study with 62 current and former smoking COPD patients and 49 controls. DNA was extracted from stool samples, and the V3V4-region of the bacterial 16S-rRNA gene was sequenced. Emphysema was defined based on thoracic computed tomography (CT thorax) low attenuating areas ≥/<10% at threshold -950 and -910 Hounsfield units respectively. Microbial data were analysed with QIIME 2 and R.</span></p> <p><strong><span>Results</span></strong></p> <p><span>The genus Veillonella was decreased and a genus belonging to class Clostridia was increased in COPD compared to healthy controls. Beta diversity measure Bray Curtis differed in emphysema compared to controls, and 27 genera were differentially abundant in emphysema vs. controls. Nine of these genera belonged to the family Lachnospiraceae. Lung function, blood counts and COPD assessment test scores were correlated with the relative abundance of several genera. Some of the genera showing the strongest correlation to lung function belonged to the family Lachnospiraceae. </span></p> <p><strong><span>Conclusion</span></strong></p> <p><span>We found small but statistically significant differences in the gut microbiota of COPD versus controls. Larger differences were seen in the gut microbiota according to CT-verified emphysema status. Correlations between the gut microbiota and lung function, blood cell counts, and CAT score were found. </span></p>
Sildenafil for Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT00104637. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
ClinicalTrials.gov study NCT03574363. IPD Sharing: NO. Countries: 1. Publications: 2.
Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
ClinicalTrials.gov study NCT05944016. IPD Sharing: YES. Countries: 1. Publications: 2.
Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT00595114. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
ClinicalTrials.gov study NCT02876835. IPD Sharing: YES. Countries: 39. Publications: 5.
20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
ClinicalTrials.gov study NCT01906489. IPD Sharing: NO. Countries: 1. Publications: 2.
Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.
ClinicalTrials.gov study NCT00298363. IPD Sharing: Not stated. Countries: 11. Publications: 1.
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT01316913. IPD Sharing: YES. Countries: 10. Publications: 2.
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT02207829. IPD Sharing: YES. Countries: 13. Publications: 2.
Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease
ClinicalTrials.gov study NCT04727528. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects
ClinicalTrials.gov study NCT00888290. IPD Sharing: NO. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.